Helixmith Co., Ltd (KOSDAQ:084990)
South Korea · Delayed Price · Currency is KRW 5,660.00
+210.00 (3.85%)
Nov 20, 2025, 3:30 PM KST
Helixmith Revenue
Helixmith had revenue of 612.74M KRW in the quarter ending June 30, 2025, a decrease of -14.95%. This brings the company's revenue in the last twelve months to 4.98B, up 57.12% year-over-year. In the year 2024, Helixmith had annual revenue of 4.97B with 18.38% growth.
Revenue (ttm)
4.98B
Revenue Growth
+57.12%
P/S Ratio
50.40
Revenue / Employee
85.85M
Employees
58
Market Cap
250.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.97B | 772.35M | 18.38% |
| Dec 31, 2023 | 4.20B | 1.40B | 50.08% |
| Dec 31, 2022 | 2.80B | 483.36M | 20.87% |
| Dec 31, 2021 | 2.32B | -1.93B | -45.48% |
| Dec 31, 2020 | 4.25B | -206.22M | -4.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |
Helixmith News
- 8 months ago - P/E Ratio Insights for Vipshop Holdings - Benzinga
- 1 year ago - Price Over Earnings Overview: Vipshop Holdings - Benzinga